Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines
The role of cytoreductive nephrectomy (CN) patients with metastatic renal cell carcinoma
(mRCC) is unclear. To define the proportion of symptomatic mRCC, to investigate the impact …
(mRCC) is unclear. To define the proportion of symptomatic mRCC, to investigate the impact …
The association between small primary tumor size and prognosis in metastatic renal cell carcinoma: insights from two independent cohorts of patients who underwent …
RG DiNatale, W Xie, MF Becerra, AW Silagy… - European urology …, 2020 - Elsevier
Background One of the main challenges in the management of renal cell carcinoma (RCC)
is risk-stratifying patients who present with metastatic disease. Tumor size is an important …
is risk-stratifying patients who present with metastatic disease. Tumor size is an important …
[HTML][HTML] Combination drug regimens for metastatic clear cell renal cell carcinoma
VV Khetani, DE Portal, MR Shah, T Mayer… - World journal of …, 2020 - ncbi.nlm.nih.gov
Renal cell carcinomas (RCC) make up about 90% of kidney cancers, of which 80% are of
the clear cell subtype. About 20% of patients are already metastatic at the time of diagnosis …
the clear cell subtype. About 20% of patients are already metastatic at the time of diagnosis …
[PDF][PDF] Хирургическое лечение местнораспространенного и метастатического рака почки
АИ Новиков, РВ Леоненков… - Практическая …, 2020 - practical-oncology.ru
Несмотря на большие успехи лекарственной терапии при распространенных формах
почечноклеточного рака, значение хирургического лечения метастатического и …
почечноклеточного рака, значение хирургического лечения метастатического и …
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review
A Rizzo, V Mollica, FG Dall'Olio, AD Ricci… - Future …, 2021 - Future Medicine
Aims: Quality of life (QoL) assessment is frequently not included among the end points of
clinical trials (CTs) on renal cell carcinoma. Herein we aimed to describe the assessment …
clinical trials (CTs) on renal cell carcinoma. Herein we aimed to describe the assessment …
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor–targeted Therapy in Patients with Primary Metastatic Clear …
R de Bruijn, A Wimalasingham, B Szabados… - European urology …, 2020 - Elsevier
Abstract Background Cancer du Rein Métastatique Nephrectomie et Antiangiogéniques
(CARMENA) concluded that sunitinib alone is not inferior to cytoreductive nephrectomy (CN) …
(CARMENA) concluded that sunitinib alone is not inferior to cytoreductive nephrectomy (CN) …
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news
F Zambrana, L Carril-Ajuria, AG de Liaño… - Cancer Treatment …, 2021 - Elsevier
Immune-checkpoint inhibitor-based therapy has revolutionized the natural history of
metastatic renal cell carcinoma (mRCC) providing better survival outcomes, higher rates of …
metastatic renal cell carcinoma (mRCC) providing better survival outcomes, higher rates of …
[HTML][HTML] Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment
A Meerveld-Eggink, N Graafland, S Wilgenhof… - European Urology Open …, 2022 - Elsevier
Following CARMENA and SURTIME, patients with metastatic renal cell carcinoma (mRCC)
and International Metastatic RCC Database Consortium (IMDC) intermediate and poor risk …
and International Metastatic RCC Database Consortium (IMDC) intermediate and poor risk …
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma
AW Silagy, RR Kotecha, S Weng, A Holmes, N Singla… - Cancer, 2021 - Wiley Online Library
Background Systemic responses to cytoreductive nephrectomy (CN) in the management of
metastatic renal cell carcinoma (mRCC) are variable and difficult to anticipate. The authors …
metastatic renal cell carcinoma (mRCC) are variable and difficult to anticipate. The authors …
CircEHD2, CircNETO2 and CircEGLN3 as diagnostic and prognostic biomarkers for patients with renal cell carcinoma
Simple Summary Circular RNA (circRNA) plays an important role in cancer, but little is
known about its role in clear cell renal cell carcinoma (ccRCC). The study was designed to …
known about its role in clear cell renal cell carcinoma (ccRCC). The study was designed to …